Vaxcyte Inc. (PCVX) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 31.01 High: 32.30

52 Week Range

Low: 27.66 High: 121.06

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $3,947 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    1.19

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0.02

  • ROEROE information

    -0.2 %

  • ROCEROCE information

    -19.97 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    27.1

  • EPSEPS information

    -3.8

7 Years Aggregate

CFO

$-713.03 Mln

EBITDA

$-835.07 Mln

Net Profit

$-930.03 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vaxcyte (PCVX)
-61.81 -58.13 -64.55 -48.61 10.45 -- --
BSE Sensex*
2.27 4.06 4.74 8.66 11.85 20.59 11.12
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 22-Apr-2025  |  *As on 23-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
2021
Vaxcyte (PCVX)
30.07 30.97 101.56 -10.46
S&P Small-Cap 600
7.01 13.89 -17.42 25.27
BSE Sensex
8.10 18.74 4.44 21.99

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
36.48 9,808.03 20.22 23.13
282.28 8,956.09 22.08 58.42
25.74 9,559.25 -- -28.77
101.74 10,030.35 30.81 14.16

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational...  pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070  Read more

  • Co-Founder, CEO & Director

    Mr. Grant E. Pickering M.B.A.

  • Co-Founder, CEO & Director

    Mr. Grant E. Pickering M.B.A.

  • Headquarters

    San Carlos, CA

  • Website

    https://vaxcyte.com

Edit peer-selector-edit
loading...
loading...

FAQs for Vaxcyte Inc. (PCVX)

The total asset value of Vaxcyte Inc (PCVX) stood at $ 3,511 Mln as on 31-Dec-24

The share price of Vaxcyte Inc (PCVX) is $31.26 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Vaxcyte Inc (PCVX) has given a return of 10.45% in the last 3 years.

Vaxcyte Inc (PCVX) has a market capitalisation of $ 3,947 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Vaxcyte Inc (PCVX) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vaxcyte Inc (PCVX) and enter the required number of quantities and click on buy to purchase the shares of Vaxcyte Inc (PCVX).

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070

The CEO & director of Mr. Grant E. Pickering M.B.A.. is Vaxcyte Inc (PCVX), and CFO & Sr. VP is Mr. Grant E. Pickering M.B.A..

There is no promoter pledging in Vaxcyte Inc (PCVX).

Vaxcyte Inc. (PCVX) Ratios
Return on equity(%)
-20.41
Operating margin(%)
--
Net Margin(%)
--
Dividend yield(%)
--

No, TTM profit after tax of Vaxcyte Inc (PCVX) was $-464 Mln.